|
|
Post by wgreystone on Sept 26, 2016 17:03:51 GMT -5
MNKD should have the urgency to negotiate with insurance companies to remove prior authorization restriction. Offering whatever necessary to have the restriction removed, either lower Afrezza price by 20%, or put more cartridges into the box and keep per-box price unchanged.
With prior authorization restriction, doctors have no incentive to prescribe Afrezza, as each minute they spend on filling up the form means lost money to them.
|
|
|
|
Post by straightly on Sept 27, 2016 20:00:08 GMT -5
MNKD should have the urgency to negotiate with insurance companies to remove prior authorization restriction. Offering whatever necessary to have the restriction removed, either lower Afrezza price by 20%, or put more cartridges into the box and keep per-box price unchanged. With prior authorization restriction, doctors have no incentive to prescribe Afrezza, as each minute they spend on filling up the form means lost money to them. If price were the only or an important factor for the pre-author, it should be considered to sell below costs to improve cashflow and awareness. We can/should raise price when Afrezz's superiority can be shown: One needs meaningful patients count to do that. |
|
|
|
Post by mannmade on Sept 27, 2016 20:05:59 GMT -5
Given the complexity of drug pricing with insurance companies and middlemen like Express Scripts and the fact that AFREZZA is now within the same price range as Novolog and Humalog I do not personally think we should be lowering the price at this time. Especially given the current environment in Congress re; Pharma and drug prices/increases. Our likely next president has already gone on record as saying this is an issue that needs to be dealt with... so it may not be easy to raise prices in the future depending on any forthcoming regulations... And imho price is not the real obstacle.
|
|
|
|
Post by sophie on Sept 27, 2016 20:19:45 GMT -5
And imho price is not the real obstacle. This appears to be correct. With the coupon card, price probably is not the issue. It's actually highly likely that anyone that has a tiered copay insurance plan would already get Afrezza cheaper than any other insulin. Even for those who have a deductible to meet, with the help of the coupon card in lowering prices, it's still pretty likely that Afrezza would be cheaper than a competitor at full retail. |
|
|
|
Post by spiro on Sept 27, 2016 20:44:48 GMT -5
mannmade,
I have never heard Trump talk about this issue.
|
|
|
|
Post by sportsrancho on Sept 27, 2016 20:54:07 GMT -5
mannmade, I have never heard Trump talk about this issue. I'll check Fact Finders..... Yep Spiro's right:-))) |
|
|
|
Post by mannmade on Sept 27, 2016 21:00:46 GMT -5
All in good fun...  among friends... |
|
|
|
Post by gonetotown on Sept 27, 2016 21:08:28 GMT -5
And imho price is not the real obstacle. This appears to be correct. With the coupon card, price probably is not the issue. It's actually highly likely that anyone that has a tiered copay insurance plan would already get Afrezza cheaper than any other insulin. Even for those who have a deductible to meet, with the help of the coupon card in lowering prices, it's still pretty likely that Afrezza would be cheaper than a competitor at full retail. How many are coupon cards have been issued? How many have used it? |
|
|
|
Post by babaoriley on Sept 28, 2016 1:17:43 GMT -5
mannmade, I have never heard Trump talk about this issue. You know where I stand on this, Spiro, but if the two unlikely events were tied together (trump wins and MNKD wins), heck, I might just go along with it. Written like a man of unshakable principles!  |
|
|
|
Post by mnholdem on Sept 28, 2016 7:22:32 GMT -5
mannmade, I have never heard Trump talk about this issue. Talk about timing...
Clinton, Trump Share Big-Pharma Attack Goals, Andrew Left Says
Attacking Big Pharma price gougers may be all that unifies the candidates ahead of tonight's debate.
James Passeri
Sep 26, 2016 3:42 PM EDT
Excerpt:
It would seem obvious that Valeant Pharmaceuticals (VRX) CEO Joseph Papa would prefer to see anyone seated in the Oval Office next January other than one of his firm's most vociferous critics, Hillary Clinton.
But a Trump presidency would be no walk in the park for the debt-laden drugmaker either -- especially given Valeant's heavy reliance on Medicare payouts and disproportionate U.S. footprint.
"Regulating the price of pharmaceuticals and eliminating price gouging might be the only issue that Trump and Hillary both agree on," Andrew Left, the short-seller who was instrumental in exposing accounting improprieties at Valeant last fall, said in a Monday phone interview with Real Money.
Source: www.thestreet.com/story/13752208/1/clinton-trump-share-big-pharma-attack-goals-andrew-left-says.html
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Sept 28, 2016 8:00:46 GMT -5
So Andrew Left is the spokesperson
|
|
|
|
Post by wgreystone on Sept 28, 2016 11:44:52 GMT -5
The coupon card helps saving patient's money, not payor's money. I believe the main concern for payors still require prior authorization two years after launch is cost. Moreover, 90 cartridges are not enough for one month supply for majority patients, especially for patients using followup correction doses.
At the stage, MNKD should really not care about margin. Remove insurance obstacles so that doctors will prescribe more prescriptions. Drug price can always be increased once Afrezza has larger user base and payors have more data to see the benefit.
|
|
|
|
Post by audiomr on Sept 28, 2016 16:27:30 GMT -5
None of us knows what insurance companies are paying for Afrezza. Castegna has said they are working diligently on the pre-auth issue.
|
|
|
|
Post by dreamboatcruise on Sept 28, 2016 16:54:43 GMT -5
The coupon card helps saving patient's money, not payor's money. I believe the main concern for payors still require prior authorization two years after launch is cost. Moreover, 90 cartridges are not enough for one month supply for majority patients, especially for patients using followup correction doses. At the stage, MNKD should really not care about margin. Remove insurance obstacles so that doctors will prescribe more prescriptions. Drug price can always be increased once Afrezza has larger user base and payors have more data to see the benefit. Yes, cost is likely the issue with payers, but it may have components that are not that simple. Companies such as Novo may well offer deals encompassing many different products and tie being a preferred supplier of certain drugs into the deal. Also, as one poster suggested "why not lure them in with lower price, and then jack it up later once patients are hooked" (paraphrasing) is something that is probably not lost on the payers. SQs will likely have biosimilars soon... Afrezza will not. Afrezza is unique... if it is a success the payers would know they would be in a bad bargaining position. Superior clinical results is what will overcome payer barriers. |
|
|
|
Post by gonetotown on Sept 28, 2016 20:15:45 GMT -5
None of us knows what insurance companies are paying for Afrezza. Castegna has said they are working diligently on the pre-auth issue. Doing what? |
|
among friends...
